A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects with Relapsed/Refractory Multiple Myeloma

Study identifier:D8310C00001

ClinicalTrials.gov identifier:NCT05850234

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

A Phase 1b/2 Study of GC012F (AZD0120), a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects with Relapsed/Refractory Multiple Myeloma

Medical condition

Relapsed/ refractory Multiple Myeloma

Phase

Phase 1/2

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

80

Study type

Interventional

Age

18 Years - n/a

Date

Study Start Date: 23 Jul 2023
Estimated Primary Completion Date: 16 Dec 2026
Estimated Study Completion Date: 05 Jun 2028

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Dec 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria